Pano Therapeutics is advancing PAN1195, a CNS-optimized biguanide, toward clinical development in Fragile X Syndrome, with a biomarker-led strategy and planned expansion in Phelan-McDermid Syndrome and Tuberous Sclerosis Complex.
Pano Therapeutics expands its scientific and clinical advisory network with leading authorities in mTOR-pathway NDDs, translational PK/PD, Fragile X Syndrome, and FXS EEG biomarkers.
Pano Therapeutics welcomes inquiries from prospective partners, investors, scientific and clinical collaborators, and the patient-advocacy community working in Fragile X Syndrome and related neurodevelopmental disorders.
Pano is a platform biotech venture focused on the clinical development of patented small molecule drugs targeting mitochondrial ion channels addressing a constellation of complex disease states.
Pano is a platform biotech venture focused on the clinical development of patented small molecule drugs targeting mitochondrial ion channels addressing a constellation of complex disease states.
